Outcomes by baseline liver function in Emerald-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma Meeting Abstract
| Authors: | Chan, S.; Decaens, T.; Kudo, M.; Erinjeri, J.; Lencioni, R.; Bouattour, M.; Breder, V.; Heo, J.; Mazzaferro, V.; Park, J. W.; Alavez, A. M.; Kee, K. M.; Xu, A. B.; Inaba, Y.; Dayyani, F.; Zotkiewicz, M.; McCoy, C.; Makowsky, M.; Sangro, B. |
| Abstract Title: | Outcomes by baseline liver function in Emerald-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma |
| Meeting Title: | Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2024): The Liver Meeting |
| Journal Title: | Hepatology |
| Volume: | 80 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Nov 15-19 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0270-9139 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2024-10-01 |
| Start Page: | S1374 |
| End Page: | S1375 |
| Language: | English |
| ACCESSION: | WOS:001366004003341 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1804 -- Source: Wos |
MSK Authors
-
200Erinjeri